Primary groups: Vaccination against typhoid fever within 5 years before dosing.
History of clinical typhoid fever, clinical paratyphoid A or B fever.
Immunization with any other vaccine (oral or parenteral) within 4 weeks prior to study start or planned vaccination during the study
Current intake of antibiotics or end of antibiotic therapy <8 days before first IMP administration
Chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of investigational vaccine; oral corticosteroids in dosages of =0.5 mg/kg/d prednisolone or equivalent are excluded; inhaled or topical steroids are allowed
Acute or chronic clinically significant gastrointestinal disease

NCT02121145_exc_T1
Observation
Primary groups
NCT02121145_exc_T2
Procedure
Vaccination against typhoid fever
NCT02121145_exc_T3
Condition
typhoid fever
NCT02121145_exc_T4
Temporal
within 5 years before dosing
NCT02121145_exc_T5
Reference_point
dosing
NCT02121145_exc_T6
Observation
History
NCT02121145_exc_T7
Condition
clinical typhoid fever
NCT02121145_exc_T8
Condition
linical paratyphoid A ever.
NCT02121145_exc_T9
Condition
linical paratyphoid  fever
NCT02121145_exc_T10
Scope
clinical typhoid fever, clinical paratyphoid A or B fever
NCT02121145_exc_T12
Procedure
munization with a ccine (
NCT02121145_exc_T13
Qualifier
any other
NCT02121145_exc_T11
Qualifier
oral
NCT02121145_exc_T14
Qualifier
parenteral
NCT02121145_exc_T15
Scope
oral or parenteral
NCT02121145_exc_T16
Temporal
within 4 weeks prior to study start
NCT02121145_exc_T17
Reference_point
study start
NCT02121145_exc_T18
Mood
planned
NCT02121145_exc_T19
Procedure
vaccination
NCT02121145_exc_T20
Temporal
during the study
NCT02121145_exc_T21
Reference_point
the study
NCT02121145_exc_T22
Drug
antibiotics
NCT02121145_exc_T23
Temporal
Current
NCT02121145_exc_T24
Multiplier
end of
NCT02121145_exc_T25
Procedure
antibiotic therapy
NCT02121145_exc_T26
Temporal
<8 days before first IMP administration
NCT02121145_exc_T27
Reference_point
first IMP administration
NCT02121145_exc_T28
Multiplier
nic (lo nistration of
NCT02121145_exc_T29
Multiplier
longer than 14 days
NCT02121145_exc_T30
Drug
immunosuppressants
NCT02121145_exc_T31
Drug
immune-modifying drugs
NCT02121145_exc_T32
Qualifier
other
NCT02121145_exc_T33
Scope
immunosuppressants or other immune-modifying drugs
NCT02121145_exc_T34
Temporal
within 6 months before the first dose of investigational vaccine
NCT02121145_exc_T35
Reference_point
the first dose of investigational vaccine
NCT02121145_exc_T36
Drug
investigational vaccine
NCT02121145_exc_T37
Drug
oral corticosteroids
NCT02121145_exc_T38
Multiplier
dosages
NCT02121145_exc_T39
Value
=0.5 mg/kg/d
NCT02121145_exc_T40
Negation
excluded
NCT02121145_exc_T41
Qualifier
prednisolone or equivalent
NCT02121145_exc_T43
Qualifier
clinically significant
NCT02121145_exc_T44
Condition
gastrointestinal disease
NCT02121145_exc_T45
Qualifier
Acute
NCT02121145_exc_T46
Qualifier
chronic
NCT02121145_exc_T47
Scope
Acute or chronic